Jejunal linoleic acid infusions require GLP-1 receptor signaling to inhibit food intake: Implications for the effectiveness of Roux-en-Y gastric bypass

American Journal of Physiology - Endocrinology and Metabolism

Volumn 301, Issue 6, 2011, Pages

  Dailey, Megan J ^a   Moghadam, Alexander A ^a   Moran, Timothy H ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Body weight; Glucagon like peptide 1; Intrajejunal infusions

Indexed keywords

EXENDIN 4; EXENDIN 9; GASTROINTESTINAL HORMONE; GLUCAGON LIKE PEPTIDE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; LINOLEIC ACID; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; BODY WEIGHT; CALORIC INTAKE; CANNULATION; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; FOOD INTAKE; GLUCAGON BLOOD LEVEL; HORMONE DETERMINATION; MALE; NONHUMAN; NUTRIENT SUPPLY; OSMOTIC PUMP; PRIORITY JOURNAL; RAT; ROUX Y ANASTOMOSIS; SIGNAL TRANSDUCTION; WEIGHT REDUCTION;

ANIMALS; APPETITE REGULATION; DOWN-REGULATION; DRUG ADMINISTRATION ROUTES; EATING; GASTRIC BYPASS; INFUSIONS, PARENTERAL; JEJUNUM; LINOLEIC ACID; MALE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, GLUCAGON; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

EID: 82355187988     PISSN: 01931849     EISSN: 15221555     Source Type: Journal    
DOI: 10.1152/ajpendo.00335.2011     Document Type: Article

References (37)

1. Abbott CR, Monteiro M, Small CJ, Sajedi A, Smith KL, Parkinson JR, Ghatei MA, Bloom SR. The inhibitory effects of peripheral administration of peptide YY(3-36) and glucagon-like peptide-1 on food intake are attenuated by ablation of the vagal-brainstem-hypothalamic pathway. Brain Res 1044: 127-131, 2005.
2. Baggio LL, Huang Q, Brown TJ, Drucker DJ. Oxyntomodulin and glucagon-like peptide-1 differentially regulate murine food intake and energy expenditure. Gastroenterology 127: 546-558, 2004.
3. Banks WA, During MJ, Niehoff ML. Brain uptake of the glucagon-like peptide-1 antagonist exendin(9 -39) after intranasal administration. J Pharmacol Exp Ther 309: 469-475, 2004.
4. Barragan JM, Eng J, Rodriguez R, Blazquez E. Neural contribution to the effect of glucagon-like peptide-1-(7-36) amide on arterial blood pressure in rats. Am J Physiol Endocrinol Metab 277: E784-E791, 1999.
5. Barrera JG, Jones KR, Herman JP, D'Alessio DA, Woods SC, Seeley RJ. Hyperphagia and increased fat accumulation in two models of chronic CNS glucagon-like peptide-1 loss of function. J Neurosci 31: 3904-3913, 2000.
6. Chelikani PK, Haver AC, Reidelberger RD. Intravenous infusion of glucagon-like peptide-1 potently inhibits food intake, sham feeding, and gastric emptying in rats. Am J Physiol Regul Integr Comp Physiol 288: R1695-R1706, 2005.
7. Cox JE, Tyler WJ, Randich A, Kelm GR, Bharaj SS, Jandacek RJ, Meller ST. Suppression of food intake, body weight, and body fat by jejunal fatty acid infusions. Am J Physiol Regul Integr Comp Physiol 278: R604-R610, 2000.
8. Dailey MJ, Tamashiro KL, Terrillion CE, Moran TH. Nutrient specific feeding and endocrine effects of jejunal infusions. Obesity (Silver Spring) 18: 904-910, 2000.
9. Flint A, Raben A, Rehfeld JF, Holst JJ, Astrup A. The effect of glucagon-like peptide-1 on energy expenditure and substrate metabolism in humans. Int J Obes Relat Metab Disord 24: 288-298, 2000.
10. Furnes MW, Stenstrom B, Tommeras K, Skoglund T, Dickson SL, Kulseng B, Zhao CM, Chen D. Feeding behavior in rats subjected to gastrectomy or gastric bypass surgery. Eur Surg Res 40: 279-288, 2008.
11. Hayes MR, Leichner TM, Zhao S, Lee GS, Chowansky A, Zimmer D, De Jonghe BC, Kanoski SE, Grill HJ, Bence KK. Intracellular signals mediating the food intake-suppressive effects of hindbrain glucagon-like peptide-1 receptor activation. Cell Metab 13: 320-330, 2000.
12. Hayes MR, Skibicka KP, Grill HJ. Caudal brainstem processing is sufficient for behavioral, sympathetic, and parasympathetic responses driven by peripheral and hindbrain glucagon-like-peptide-1 receptor stimulation. Endocrinology 149: 4059-4068, 2008.
13. Holst JJ. Enteroglucagon. Annu Rev Physiol 59: 257-271, 1997.
14. Imeryuz N, Yegen BC, Bozkurt A, Coskun T, Villanueva-Penacarrillo ML, Ulusoy NB. Glucagon-like peptide-1 inhibits gastric emptying via vagal afferent-mediated central mechanisms. Am J Physiol Gastrointest Liver Physiol 273: G920-G927, 1997.
15. Kanoski SE, Fortin SM, Arnold M, Grill HJ, Hayes MR. Peripheral and central GLP-1 receptor populations mediate the anorectic effects of peripherally administered GLP-1 receptor agonists, liraglutide and exendin-4. Endocrinology 152: 3103-3112, 2011.
16. Kastin AJ, Akerstrom V. Entry of exendin-4 into brain is rapid but may be limited at high doses. Int J Obes Relat Metab Disord 27: 313-318, 2003.
17. Korner J, Bessler M, Inabnet W, Taveras C, Holst JJ. Exaggerated glucagon-like peptide-1 and blunted glucose-dependent insulinotropic peptide secretion are associated with Roux-en-Y gastric bypass but not adjustable gastric banding. Surg Obes Relat Dis 3: 597-601, 2007.
18. Larsen PJ, Fledelius C, Knudsen LB, Tang-Christensen M. Systemic administration of the long-acting GLP-1 derivative NN2211 induces lasting and reversible weight loss in both normal and obese rats. Diabetes 50: 2530-2539, 2001.
19. Lu WJ, Yang Q, Sun W, Woods SC, D'Alessio D, Tso P. The regulation of the lymphatic secretion of glucagon-like peptide-1 (GLP-1) by intestinal absorption of fat and carbohydrate. Am J Physiol Gastrointest Liver Physiol 293: G963-G971, 2007.
20. McClean P, Fung K, McCurtin R, Gault V, Holscher C. Novel GLP-1 analogues cross the blood brain barrier: a link between diabetes and Alzheimer's disease. Soc Neurosci Meeting, Chicago, IL 2009, p. 528-529.
21. Meeran K, O'Shea D, Edwards CM, Turton MD, Heath MM, Gunn I, Abusnana S, Rossi M, Small CJ, Goldstone AP, Taylor GM, Sunter D, Steere J, Choi SJ, Ghatei MA, Bloom SR. Repeated intracerebroventricular administration of glucagon-like peptide-1-(7-36) amide or exendin-(9-39) alters body weight in the rat. Endocrinology 140: 244-250, 1999.
22. Naslund I. Gastric bypass versus gastroplasty. A prospective study of differences in two surgical procedures for morbid obesity. Acta Chir Scand Suppl 536: 1-60, 1987.
23. Nilsson PM, Roost M, Engstrom G, Hedblad B, Berglund G. Incidence of diabetes in middle-aged men is related to sleep disturbances. Diabetes Care 27: 2464-2469, 2004.
24. Nowak A, Bojanowska E. Effects of peripheral or central GLP-1 receptor blockade on leptin-induced suppression of appetite. J Physiol Pharmacol 59: 501-510, 2008.
25. Pories WJ, Swanson MS, MacDonald KG, Long SB, Morris PG, Brown BM, Barakat HA, deRamon RA, Israel G, Dolezal JM. Who would have thought it? An operation proves to be the most effective therapy for adult-onset diabetes mellitus. Ann Surg 222: 339-350, 1995.
26. Ruttimann EB, Arnold M, Geary N, Langhans W. GLP-1 antagonism with exendin (9 -39) fails to increase spontaneous meal size in rats. Physiol Behav 100: 291-296, 2000.
27. Ruttimann EB, Arnold M, Hillebrand JJ, Geary N, Langhans W. Intrameal hepatic portal and intraperitoneal infusions of glucagon-like peptide-1 reduce spontaneous meal size in the rat via different mechanisms. Endocrinology 150: 1174-1181, 2009.
28. Schauer PR, Burguera B, Ikramuddin S, Cottam D, Gourash W, Hamad G, Eid GM, Mattar S, Ramanathan R, Barinas-Mitchel E, Rao RH, Kuller L, Kelley D. Effect of laparoscopic Roux-en Y gastric bypass on type 2 diabetes mellitus. Ann Surg 238: 467-484, 2003.
29. Scott KA, Moran TH. The GLP-1 agonist exendin-4 reduces food intake in nonhuman primates through changes in meal size. Am J Physiol Regul Integr Comp Physiol 293: R983-R987, 2007.
30. Serre V, Dolci W, Schaerer E, Scrocchi L, Drucker D, Efrat S, Thorens B. Exendin-(9 -39) is an inverse agonist of the murine glucagonlike peptide-1 receptor: implications for basal intracellular cyclic adenosine 3=,5=-monophosphate levels and beta-cell glucose competence. Endocrinology 139: 4448-4454, 1998.
31. Sjostrom L, Lindroos AK, Peltonen M, Torgerson J, Bouchard C, Carlsson B, Dahlgren S, Larsson B, Narbro K, Sjostrom CD, Sullivan M, Wedel H. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med 351: 2683-2693, 2004.
32. Talsania T, Anini Y, Siu S, Drucker DJ, Brubaker PL. Peripheral exendin-4 and peptide YY(3-36) synergistically reduce food intake through different mechanisms in mice. Endocrinology 146: 3748-3756, 2005.
33. Tseng CC, Zhang XY, Wolfe MM. Effect of GIP and GLP-1 antagonists on insulin release in the rat. Am J Physiol Endocrinol Metab 276: E1049-E1054, 1999.
34. Williams DL. Expecting to eat: glucagon-like peptide-1 and the anticipation of meals. Endocrinology 151: 445-447, 2000.
35. Williams DL, Baskin DG, Schwartz MW. Evidence that intestinal glucagon-like peptide-1 plays a physiological role in satiety. Endocrinology 150: 1680-1687, 2009.
36. Xu Y, Ohinata K, Meguid MM, Marx W, Tada T, Chen C, Quinn R, Inui A. Gastric bypass model in the obese rat to study metabolic mechanisms of weight loss. J Surg Res 107: 56-63, 2002.
37. Yamamoto H, Kishi T, Lee CE, Choi BJ, Fang H, Hollenberg AN, Drucker DJ, Elmquist JK. Glucagon-like peptide-1-responsive catecholamine neurons in the area postrema link peripheral glucagon-like peptide-1 with central autonomic control sites. J Neurosci 23: 2939-2946, 2003.